Cargando…

Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer

BACKGROUND: Mismatch Repair Deficiency (MMR-D)-related tumors are highly immunogenic and constitute ideal vaccination targets. In a proof-of-concept study delayed tumorigenesis and prolonged survival has been shown in a clinically-relevant mouse model for MMR-D-related diseases (=MLH1 knock out mice...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maletzki, Claudia, Wiegele, Leonie, Nassar, Ingy, Stenzel, Jan, Junghanss, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329128/ https://www.ncbi.nlm.nih.gov/pubmed/30630527 http://dx.doi.org/10.1186/s40425-018-0476-x

Ejemplares similares

Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
por: Salewski, Inken, et al.
Publicado: (2021)

Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1(−/−) Mice
por: Gladbach, Yvonne Saara, et al.
Publicado: (2019)

Long-term survivor of metastatic squamous-cell head and neck carcinoma with occult primary after cetuximab-based chemotherapy: A case report
por: Große-Thie, Christina, et al.
Publicado: (2021)

Acquired resistance to immunotherapy in MMR-D pancreatic cancer
por: Hu, Zishuo Ian, et al.
Publicado: (2018)

Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer
por: Paffenholz, Stella V., et al.
Publicado: (2022)

Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
por: Krone, Paula, et al.
Publicado: (2023)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023)

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
por: Cortelazzo, Sergio, et al.
Publicado: (2021)

Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches
por: Richter, Anna, et al.
Publicado: (2021)

Preclinical Head and Neck Squamous Cell Carcinoma Models for Combined Targeted Therapy Approaches
por: Schoenwaelder, Nina, et al.
Publicado: (2022)

Triple‐Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo‐Immunotherapy in Preclinical Cancer Models
por: Shi, Xiaowei, et al.
Publicado: (2023)

Endometrial cancer risk and survival by tumor MMR status
por: Nagle, Christina M., et al.
Publicado: (2018)

Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm
por: Ozer, Muhammet, et al.
Publicado: (2023)

Squamous cell carcinoma of the prostate: long-term survival after combined chemo-radiation
por: Munoz, Fernando, et al.
Publicado: (2007)

Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors
por: Salewski, Inken, et al.
Publicado: (2021)

CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
por: Salewski, Inken, et al.
Publicado: (2022)

Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
por: Zhang, Yuguo, et al.
Publicado: (2022)

Bacterial immunotherapy of gastrointestinal tumors
por: Linnebacher, Michael, et al.
Publicado: (2011)

Improving health literacy with mumps, measles and rubella (MMR) vaccination: comparison of the readability of MMR patient-facing literature and MMR scientific abstracts
por: Downey, Tina, et al.
Publicado: (2022)

Chemo-Immunotherapy: A New Trend in Cancer Treatment
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
por: Zhang, Xuan, et al.
Publicado: (2022)

Heterogeneity and Adjuvant Therapeutic Approaches in MSI-H/dMMR Resectable Gastric Cancer: Emerging Trends in Immunotherapy
por: Wu, Hui, et al.
Publicado: (2023)

The need to optimize chemotherapy regimens for chemo-immunotherapy
por: Inamura, Kentaro, et al.
Publicado: (2022)

In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters
por: Salewski, Inken, et al.
Publicado: (2020)

Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy
por: Stier, Saskia, et al.
Publicado: (2013)

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2018)

Dramatic response of metaplastic breast cancer to chemo-immunotherapy
por: Adams, Sylvia
Publicado: (2017)

A mathematical model for treatment using chemo-immunotherapy
por: Nave, Ophir
Publicado: (2022)

Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
por: Wang, Zhenghang, et al.
Publicado: (2022)

Cross calibration of the Siemens mMR: easily acquired accurate PET phantom measurements, long term stability and reproducibility
por: Keller, Sune H, et al.
Publicado: (2015)

Cross-calibration of the Siemens mMR: easily acquired accurate PET phantom measurements, long-term stability and reproducibility
por: Keller, Sune H., et al.
Publicado: (2016)

Unprecedented long‐term survival in a patient with malignant pleural mesothelioma treated with subsequent systemic chemo‐ and immunotherapeutic regimens
por: Cerbone, Luigi, et al.
Publicado: (2023)

Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide
por: Brawanski, Konstantin R., et al.
Publicado: (2023)

Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?
por: Riess, Christin, et al.
Publicado: (2020)

Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
por: Ma, Yu-Ting, et al.
Publicado: (2022)

MMR gene patterns evaluation provides novel insights for personalized immunotherapy compared to neoadjuvant chemotherapy in lung adenocarcinama
por: Cai, Liangliang, et al.
Publicado: (2023)

LDH‐A negatively regulates dMMR in colorectal cancer
por: Zhang, Yongjie, et al.
Publicado: (2021)

The Clinicopathological Characteristics and Prognoses of dMMR Gastric Adenocarcinoma Patients
por: Wang, Jie, et al.
Publicado: (2021)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Cannot write session to /tmp/vufind_sessions/sess_festk5f41sfoa9p53so4c5skfh